Going-concern uncertainty
Management disclosed substantial doubt about the company's ability to continue as a going concern.
- Scope
- Liquidity, refinancing access, and operating continuity
- Materiality
- high
Inotiv, Inc.
Inotiv, Inc. is a U.S.-based contract research organization that supports drug and medical device development from discovery through preclinical testing, and in some cases clinical phases. It also supplies research models, including animals and specialized diets, to pharmaceutical, medical device, academic, and government customers.
4,9 %
−13,4 %
+4,5 %
0.35
0.27
| % | |
|---|---|
| Discovery and Safety Assessment (DSA) | 45% Nonclinical and analytical research services that help advance drug and device candidates through discovery and preclinical testing. |
| Research Models and Services (RMS) | 55% Supply of research animals, colony management, and related services used in preclinical studies. |
Inotiv sells primarily to pharmaceutical and medical device companies that need outsourced research capacity,...
- Pharmaceutical and biopharmaceutical companiesprimary
Buy toxicology, analytical, and discovery services to advance drug candidates through preclinical development.
- Medical device companiesprimary
Buy safety assessment and related testing to support device development and regulatory submissions.
- Research models customersprimary
Buy nonhuman primates, rodents, and diets for in-house or outsourced studies, often valuing supply continuity.
- Emerging biopharmaceutical companiessecondary
Use flexible DSA services during discovery and early development when study needs change quickly.
- Academia and governmentsecondary
Purchase research animals and related products for scientific research and testing programs.
Inotiv is headquartered in West Lafayette, Indiana, and serves major research markets from North America and the U.K...
- •Headquartered in West Lafayette, Indiana, United States
- •Commercial teams operate in North America and U.K./Europe
- •12.7% of fiscal 2025 revenue came from outside the U.S.
- •International operations add currency, tax, and regulatory exposure
- •Global reach supports CRO clients and research-model distribution
Management is focused on improving operating results through client service, margin discipline, and better capital...
01
Grow DSA study volume and contract awardsshort-term
DSA is the higher-value service engine and broadens the company’s CRO offering.
02
Expand RMS revenue and colony management capacitymedium-term
RMS provides recurring demand and benefits from customer preference for consistent models.
03
Optimize capital allocation and expense baseshort-term
The company is under pressure to improve margins and preserve liquidity.
Inotiv faces a going-concern and covenant-compliance risk profile that can constrain financing and operating...
Debt covenant noncompliance
The fiscal 2026 operating plan forecasts noncompliance with financial covenants under the Credit Agreement.
- Scope
- Potential default, lender negotiations, and restricted financing
- Materiality
- high
International operating exposure
12.7% of revenue came from outside the U.S., creating FX, tax, labor, and regulatory exposure.
- Scope
- U.K./Europe and other non-U.S. facilities
- Materiality
- medium
RMS pricing pressure
RMS revenue fell due primarily to lower pricing in connection with NHP sales.
- Scope
- Research models and nonhuman primate-related revenue
- Materiality
- high
Client demand cyclicality
Customer needs vary with research stage, causing turnover and uneven demand.
- Scope
- DSA study volumes and RMS recurring orders
- Materiality
- medium
Revenue recognition under ASC 606
Can shift revenue between periods for DSA and RMS
Goodwill and intangible assets
Potential non-cash charges if performance weakens
Long-lived asset estimates
Depreciation and possible impairment charges
Contingencies and litigation accruals
Can materially affect expenses and liabilities
Debt and covenant accounting
May affect current/non-current debt presentation and going-concern assessment
: 28.4.2026